Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | HCT in MDS: cell source and conditioning type

Fernando Barroso Duarte • 30 Aug 2020
EBMT 2020
Myelodysplastic Syndromes Antibodies Busulfan Cyclophosphamide Elotuzumab Fludarabine Melphalan

Fernando Barroso Duarte, MD, Federal University of Ceara, Clinical Hospital, Fortaleza, Brazil, discusses the influence of cell source and conditioning type on hematopoietic cell transplantation (HCT) in myelodysplastic syndromes (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Fernando Barroso Duarte

Allogeneic transplantation in elderly patients: insights from Brazilian registry data 2:23
Allogeneic transplantation in elderly patients: insights from Brazilian registry data
Fernando Barroso Duarte • 30 Mar 2025
Allogeneic transplantation for CMML from the Latin American perspective 2:20
Allogeneic transplantation for CMML from the Latin American perspective
Fernando Barroso Duarte • 30 Mar 2025
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT 6:04
Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT
Fernando Barroso Duarte • 12 May 2023
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era 3:31
Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era
Fernando Barroso Duarte • 13 Feb 2023

Related Videos

GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
Ask the Expert: Charles Craddock answers your transplantation questions at iwAL 2025 17:27
Ask the Expert: Charles Craddock answers your transplantation questions at iwAL 2025
Charles Craddock • 21 Sep 2025
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025 11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025
Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
The content of VJHemOnc is intended for healthcare professionals